Leveraging modular TriKE-PACC molecules capable of dual-antigen targeting to enhance NK-cell immunotherapy in AML 2257266
The engineered TriKEs with Poly Antigen Cytokine Complexes (TriKE-PACCs), which combine dual AML-specific targeting with NK activation and persistence, enhance NK cell proliferation and antitumor activity compared to TriKEs or IL-15 therapies alone.